The statements in this press release that are not historical facts or
information may be forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results
and outcomes to be materially different. Certain of these risks and
uncertainties may include, but are not limited to, competitive environment,
changes in government regulations, changing relationships with customers,
payers, suppliers and strategic partners and other factors described in the
Quest Diagnostics Incorporated 2007 Form 10-K and subsequent SEC filings.
(1) American Cancer Society - Cancer Facts & Figures 2008.
(2) Solomon D et al. Cervical Cancer Screening Rates in the United States
and Potential Impact of Implementation of Screening Guidelines. CA
Cancer J Clin 2007; 57; 105-111.
(3) Ferrini R et al. Screening for prostate cancer in American men.
American College of Preventive Medicine Practice Policy Statement.
(4) Smith A, et al. Comparison of a brush-sampling fecal immunochemical
test for hemoglobin with a sensitive guaiac-based fecal occult blood
test in detection of colorectal neoplasia. Cancer 2006; 107:2152-2159.
(5) Cole SR, Young GP, Esterman A, Cadd A, Morcom J. A randomised trial of
the impact of new faecal haemoglobin test technologies on population
participation in screening for colorectal cancer. J Med Screen
|SOURCE Quest Diagnostics|
Copyright©2008 PR Newswire.
All rights reserved